Indication
As an adjunct to diet and exercise for the treatment of obese patients (BMI 30 kg/m2), or overweight patients (BMI 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).
Loading your page…
Loading your page…
Obesity
Marketing Authorisation Holder: sanofi-aventis
EMA Authorisation: 19/06/2006
INN: rimonabant
AI Drug & Interaction Analysis
Free account required
Ask Osler about Acomplia: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.